PROGRESS TOWARDS AN A‐SYNUCLEIN PET TRACER

The high value for Parkinson’s disease and related disorders of the availability of a potent, selective, brain penetrant α‐synuclein (α‐Syn) PET tracer is widely acknowledged. We aimed to develop such an agent by applying an established radiotracer development strategy that has been successfully used with another misfolded CNS protein target.